Suzhou Basecare Medical (HKSE:02170) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Suzhou Basecare Medical is: High Risk: High uncertainty.

Competitive Comparison of Suzhou Basecare Medical's Risk Assessment

For the Medical Devices subindustry, Suzhou Basecare Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suzhou Basecare Medical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Suzhou Basecare Medical (HKSE:02170) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Suzhou Basecare Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices, instruments, and consumables. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. Geographically the company generates the majority of its revenue from the PRC.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager

Suzhou Basecare Medical Headlines

No Headlines